Efficacy and Safety of MITSU AB™ Triclosan-Coated Sutures in Preventing Surgical Site Infections

Surgical site infections (SSIs) are a significant source of postoperative morbidity. Triclosan-coated absorbable sutures, such as MITSU AB™ (Meril Endo Surgery Private Limited, Vapi, India), are designed to inhibit early microbial colonization, reducing the risk of SSIs. However, concerns about triclosan resistance highlight the need for real-world clinical evaluation. The present study aims to assess wound healing outcomes, incidence of SSIs, and triclosan resistance in patients treated with MITSU AB™ absorbable triclosan-coated sutures.

A prospective, single-arm, multi-center post-marketing surveillance study was conducted involving 60 patients undergoing general surgical procedures, including laparoscopic appendectomy, episiotomy, and soft tissue repair. Patients were monitored postoperatively at discharge and days 7, 15, and 30. Primary outcomes included SSI occurrence and triclosan resistance. Secondary endpoints were wound healing grade, pain (measured by visual analogue scale (VAS)), and suture handling feedback.

The study population had a mean age of 38.5 ± 17.4 years, with 36 (60%) female participants. All patients (100%) achieved complete wound healing (Grade A) by day 30. No SSIs, triclosan-resistant microbial growth, or adverse events were recorded. Pain scores decreased over time, with 59 (98.3%) patients pain-free by day 15 and 100% by day 30. Suture handling was rated excellent in 51 (85%) cases. No re-interventions or re-admissions due to infection occurred during the study.

MITSU AB™ triclosan-coated sutures demonstrated excellent infection prevention, complete healing, and favorable handling with no evidence of triclosan resistance. These findings support their safe and effective use in clinical surgery.